PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

BRAF inhibitors (BRAFi) selectively target oncogenic BRAF(V600E/K) and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy. Better characterization of the underlying molecular proce...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Sci Rep
Hoofdauteurs: Vidarsdottir, Linda, Azimi, Alireza, Das, Ishani, Sigvaldadottir, Ingibjorg, Suryo Rahmanto, Aldwin, Petri, Andreas, Kauppinen, Sakari, Ingvar, Christian, Jönsson, Göran, Olsson, Håkan, Frostvik Stolt, Marianne, Tuominen, Rainer, Sangfelt, Olle, Pokrovskaja Tamm, Katja, Hansson, Johan, Grandér, Dan, Egyházi Brage, Suzanne, Johnsson, Per
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group UK 2021
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8155038/
https://ncbi.nlm.nih.gov/pubmed/34040017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-89389-9
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items